What can breast and lung cancer oncologists learn from each other about TROP2-directed antibody-drug conjugates?

Dr. Komal Jhaveri, Dr. Paolo Tarantino, and Dr. Jacob Sands discuss the role of datopotamab deruxtecan (Dato-DXd) across breast and lung cancer, examining clinical trial findings, patient selection, and practical approaches to treatment.

Drawing on the TROPION-Breast and TROPION-Lung trials, they address differences in efficacy across patient populations, emerging biomarkers, toxicity management, and the challenges of ADC sequencing and resistance.

Topics discussed:

• Dato-DXd efficacy in breast and lung cancer

• TROPION-Breast01, TROPION-Breast02, TROPION-Lung01, and TROPION-Lung05 findings

• EGFR mutations and TROP2 biomarkers

• Brain metastases and intracranial activity

• Dato-DXd and sacituzumab govitecan

• Stomatitis, ocular toxicity, and ILD management

• ADC sequencing and cross-resistance

• Next-generation ADC strategies

Watch the full CHM Conversation for expert perspectives on translating Dato-DXd evidence across breast and lung cancer into clinical practice.

▶️ https://youtu.be/e2aWLCMD_mk

#KomalJhaveri #PaoloTarantino #JacobSands #CHMConversations #DatoDXd #TROP2 #AntibodyDrugConjugates #BreastCancer #LungCancer #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

When an ESR1 mutation emerges before radiographic progression, what comes next?

Dr. Jason Mouabbi, Dr. Joyce O'Shaughnessy, and Dr. Erica Mayer discuss findings from the SERENA-6 trial, focusing on the use of circulating tumor DNA (ctDNA) to identify emerging ESR1 mutations during first-line endocrine therapy.

They examine the progression-free survival benefit observed when patients with newly detected ESR1 mutations switched from an aromatase inhibitor to camizestrant while continuing their existing CDK4/6 inhibitor. The conversation also addresses ctDNA response findings, patient-reported quality-of-life outcomes, and the practical considerations of implementing molecular surveillance before radiographic progression.

Topics discussed:

• ESR1 mutations as a mechanism of endocrine resistance

• SERENA-6 trial design and progression-free survival findings

• ctDNA clearance and changes in ESR1 variant allele frequency

• Patient-reported quality-of-life outcomes and time to chemotherapy

• Camizestrant safety considerations, including photopsia, bradycardia, and QTc monitoring

• Timing and implementation of ESR1 mutation testing

• Continuing CDK4/6 inhibition after an endocrine therapy switch

• Unanswered questions about oral SERD sequencing and future treatment strategies

Watch the full CHM Conversation to hear how these experts interpret the SERENA-6 findings and discuss their potential application in clinical practice.

▶️ https://youtu.be/bcvuFLVWBmE

#JasonMouabbi #JoyceOShaughnessy #EricaMayer #CHMConversations #SERENA6 #Camizestrant #ESR1 #ctDNA #OralSERDs #MetastaticBreastCancer #EndocrineResistance #CDK46Inhibitors #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

How are TROP2-directed antibody-drug conjugates (ADCs) changing treatment decisions in breast and lung cancer?

Dr. Jason Mouabbi is joined by Dr. Rebecca Shatsky and Dr. Ryan Gentzler to discuss the clinical evidence behind datopotamab deruxtecan (Dato-DXd), its role across breast and lung cancer, and the challenges of selecting and sequencing ADC therapies.

Drawing on findings from TROPION-Breast02, ASCENT-03, TROPION-Lung01 and TROPION-Lung05, they examine efficacy, emerging data in brain metastases, treatment-related toxicities, and the potential of ADC combinations with immunotherapy and targeted agents.

Topics discussed:

• Dato-DXd and sacituzumab govitecan in metastatic TNBC

• TROP2 ADCs in EGFR-mutated lung cancer

• Brain metastases and intracranial activity

• ADC sequencing and treatment selection

• Managing stomatitis, ocular toxicity, and ILD

• Emerging ADC combinations and future directions

Watch the full CHM Conversation for expert perspectives on translating ADC evidence into treatment decisions across breast and lung oncology.

▶️ https://youtu.be/99AchJ1ZlnU

#JasonMouabbi #RebeccaShatsky #RyanGentzler #CHMConversations #BreastCancer #LungCancer #AntibodyDrugConjugates #DatoDXd #TROP2 #TNBC #NSCLC #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media